EXEL announced that the FDA has approved the label expansion of its lead drug Cabometyx (cabozantinib). The regulatory body approved Cabometyx for the treatment of adult and pediatric patients 12 ...

EXEL stock gains on the back of encouraging performance of its lead drug Cabometyx and efforts to improve shareholder value. However, the recent rally might limit further gains for shareholders.

Roche’s closely-watched combination of two checkpoint inhibitors – TIGIT-targeting tiragolumab and PD-L1 drug Tecentriq ... response seen with Tecentriq (atezolizumab) alone.

AZ has struggled to extend the label of Imfinzi beyond that in NSCLC, other than a 2022 approval for the drug in combination ... as is Roche’s Tecentriq (atezolizumab), with a similar indication ...

Exelixis (EXEL) wins FDA approval for Cabometyx for advanced pancreatic and extra pancreatic neuroendocrine tumors in ...

This expanded indication for Amvuttra makes it the first and only FDA-approved treatment for transthyretin amyloidosis with ...

Approval was based on findings from the pivotal CABINET trial showing improved PFS and response rates vs placebo.

In March 2025, Merck Sharp & Dohme LLC announced a study are to learn if people who receive V940 and pembrolizumab are alive ...

According to Telix Pharmaceuticals, the product has a longer shelf-life (up to 6 hours) and an extended distribution radius compared with other gallium-based products.

Exelixis, Inc announced that the U.S. Food and Drug Administration (FDA ... Inc announced the completion of enrollment in the open-label KONFIDENT-KID clinical trial of sebetralstat, an ...

Detailed price information for Sonnet Biotherapeutics Holdings Inc (SONN-Q) from The Globe and Mail including charting and trades.